Palvella Therapeutics (PVLA) Asset Utilization Ratio (2014 - 2024)
Palvella Therapeutics (PVLA) posted quarterly Asset Utilization Ratio of 0.12 for Q3 2024, down 121.23% year-over-year from 0.57 in Q4 2023, and down 119.6% quarter-over-quarter from 0.61 in Q2 2024.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Asset Utilization Ratio (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Asset Utilization Ratio for 11 consecutive years, with 0.12 the latest figure, recorded in Q3 2024.
- In Q3 2024, Asset Utilization Ratio fell 121.23% year-over-year to 0.12; the TTM figure through Sep 2024 stood at 0.12 (down 121.23% YoY), while the FY2023 annual figure was 0.75, up 21509.05% from the prior year.
- Asset Utilization Ratio slipped to 0.12 in Q3 2024 per PVLA's latest filing, from 0.61 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 1.99 in Q1 2024 and bottomed at 0.12 in Q3 2024.
- Historically, Asset Utilization Ratio has averaged 0.38 across 5 years, with a median of 0.21 in 2021.
- On a YoY basis, Asset Utilization Ratio climbed as much as 6606.14% in 2024 and fell as far as 121.23% in 2024.
- Palvella Therapeutics' Asset Utilization Ratio stood at 0.21 in 2020, then retreated by 21.53% to 0.17 in 2021, then dropped by 27.77% to 0.12 in 2022, then soared by 871.4% to 1.16 in 2023, then sank by 110.4% to 0.12 in 2024.
- Business Quant data shows PVLA's Asset Utilization Ratio at 0.12 in Q3 2024, 0.61 in Q2 2024, and 1.99 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.20 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.69 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 0.90 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.13 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.54 |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 0.06 |
| Jun 30, 2024 | 0.77 |
| Mar 31, 2024 | 2.21 |
| Dec 31, 2023 | 1.28 |
| Sep 30, 2023 | 0.65 |
| Jun 30, 2023 | 0.39 |
| Mar 31, 2023 | 0.19 |
| Dec 31, 2022 | 0.27 |
| Sep 30, 2022 | 0.27 |
| Jun 30, 2022 | 0.22 |
| Mar 31, 2022 | 0.19 |
| Dec 31, 2021 | 0.18 |
| Sep 30, 2021 | 0.14 |
| Jun 30, 2021 | 0.16 |
| Mar 31, 2021 | 0.26 |
| Dec 31, 2020 | 0.27 |
| Sep 30, 2020 | 0.38 |
| Jun 30, 2020 | 0.47 |
| Mar 31, 2020 | 0.39 |
| Dec 31, 2019 | 0.36 |